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Abstract
Candida albicans is a dimorphic fungus that can grow in yeast morphology or hyphal form depending
on the surrounding environment. This ubiquitous fungus is present in skin and mucus membranes
as a potential pathogen that under opportunistic conditions causes a series of systemic and
superficial infections known as candidiasis, moniliasis or simply candidiasis. There has been a steady
increase in the prevalence of candidiasis that is expressed in more virulent forms of infection.
Although candidiasis is commonly manifested as mucocutaneous disease, life-threatening systemic
invasion by this fungus can occur in every part of the body. The severity of candidal infections is
associated with its morphological shift such that the hyphal morphology of the fungus is most
invasive. Of importance, aberrant multiplication of Candida  yeast is also associated with the
pathogenesis of certain mucosal diseases. In this study, we assessed the anti-candidal activity of the
volatile anesthetic isoflurane in liquid form in comparison with the anti-fungal agent amphotericin
B in an in vitro culture system. Exposure of C. albicans to isoflurane (0.3% volume/volume and above)
inhibited multiplication of yeast as well as formation of hyphae. These data suggest development of
potential topical application of isoflurane for controlling a series of cutaneous and genital infections
associated with this fungus. Elucidiation of the mechanism by which isoflurane effects fungal growth
could offer therapeutic potential for certain systemic fungal infections.
Background
Candida albicans is an opportunistic fungal pathogen
mainly causing infections among immunocompromised
individuals [1]. Infections associated with this fungus
range from superficial mycoses to life threatening sys-
temic candidiasis, which involve various body organs and
invasive mucosal disorders. A wide spectrum of infections
associated with C. albicans are ascribed to the capability of
this fungus to switch between unicellular budding yeast to
multicellular, filamentous mycelial or hyphal form [2].
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Several studies in the past have reported that the hyphal
form of C. albicans is more invasive compared with bud-
ding yeast [2-4]. This hypothesis has been further
strengthened in a rodent model of fungal infection where
C. albicans strains unable to form hyphae were essentially
avirulent [5]. As such, there has always been a need for an
antifungal agent that can both prevent the formation of
hyphae as well as destroy both yeast and hyphal morphol-
ogies of this fungus.
Isoflurane is a halogenated volatile anesthetic and its gas-
eous form has shown antibacterial activity against one of
the most common bacterial pathogens in hospital-
acquired pneumonia Pseudomonas aeruginosa [6]. One
study on the other hand did not find any antibacterial
activity of isoflurane against Staphylococcus aureus and
Escherichia coli [7]. Prospects for clinical usage of the gase-
ous isoflurane as an antibacterial agent have been ham-
pered due to adverse systemic effects and occupational
hazards [8,9]. Encouraged by our initial data showing that
the gaseous form of isoflurane inhibits C. albicans mor-
phogenesis (formation of hyphae from yeast cells, unpub-
lished data), we analyzed the anti-candidal potential of
volatile liquid isoflurane. C. albicans in vitro cultures were
treated with various concentrations of isoflurane in semi-
anaerobic as well as aerobic environments. Growth
behavior and morphological changes were then assessed.
For our initial studies, semi-anaerobic study design was
essentially based on the volatile nature of the isoflurane
with the challenge to maintain uniform concentrations of
volatile anesthetic in the in vitro culture. Moreover, like
several other fungi, C. albicans is a facultative anaerobe
and can fulfill energy requirements either in the presence
of oxygen or in the absence via fermentation [10]. Intrigu-
ingly, aerobic cultures of the yeast treated with isoflurane
also revealed inhibitory effects on both yeast multiplica-
tion and formation of hyphae. We observed that isoflu-
rane could completely abolish formation of hyphae in C.
albicans, a step essential for the pathogenesis of this fun-
gus  in vivo. A concentration of 0.5% isoflurane (v/v)
showed fungicidal activity equivalent to amphotericin B,
4.0  µg/ml a concentration that has been previously
reported as fungicidal [11]. Moreover, C. albicans treated
with lower concentrations of isoflurane (0.1 – 0.4%)
showed diminished growth. These findings are highly sig-
nificant, as this approach will provide a platform for a sys-
tematic study of fungal morphogenesis at the molecular
level. Moreover, isoflurane in gaseous form is a widely
used anesthetic approved by the U.S. Food and Drug
Administration (FDA). Although usage of the gaseous
form of isoflurane to treat systemic infections may not be
feasible due to its anesthetic actions as well as adverse car-
diovascular effects at high concentrations, however, possi-
bilities exist for manipulation of the antimicrobial
potentials of isoflurane. This is the first report revealing
liquid isoflurane-mediated control of C. albicans growth
and morphogenesis in a concentration-dependent man-
ner. These findings suggest that there may be an opportu-
nity to develop topical microbicides based on creative
formulations that modulate the release of isoflurane. This
strategy may provide a means for controlling Candida and
related superficial infections that affect millions of immu-
nocompromised and healthy individuals worldwide.
Results
Effects of liquid isoflurane on the metabolic activity of C. 
albicans
In our pilot studies we evaluated the effects of clinically
relevant concentrations of gaseous isoflurane on C. albi-
cans morphogenesis and observed an inhibitory effect on
the formation of true hyphae from the yeast form of this
fungus (data not illustrated). Encouraged by our initial
observations we further analyzed the effects of various
concentrations of liquid isoflurane on the morphogenesis
and growth of C. albicans.
Isoflurane concentrations of 0.1% (v/v) and higher signif-
icantly inhibited metabolic activity of C. albicans (p <
0.001 compared to control), however, a concentration of
0.4–0.5% (v/v) was critical in this study to achieve inhib-
itory activity similar to that of amphotericin B (4.0 µg.mL)
(Fig 1B). Concentrations of liquid isoflurane less than
0.1% (v/v) did not significantly inhibit metabolic activity
(determined by the fungi-derived gas volume displace-
ment in syringe culture) of C. albicans in a semi-anaerobic
environment. (Fig. 1A).
Effect of isoflurane on candidal growth and multiplication
Isoflurane concentrations of 0.1% (v/v) and above were
inhibitory to yeast multiplication with concentrations of
0.2% or higher having an effect similar to amphotericin B
in a semi-anaerobic environment (Fig. 2). Furthermore,
even at the lowest concentration (0.05%) liquid isoflu-
rane completely inhibited the formation of hyphae in
semi-anaerobic conditions (Fig. 3).
Although lower concentrations (0.1 – 0.3%) of isoflurane
revealed inhibitory effects on growth, viability assays of
the cultures treated with these concentrations indicated
that the yeast were capable of forming hyphae equivalent
to control cultures (Figure 4). However, at isoflurane con-
centrations of 0.3% and above we observed a significant
inhibitory effect on the formation of hyphae. When com-
pared with positive control amphotericin B, a well-charac-
terized and clinically used antifungal agent, a
concentration of 0.4% isoflurane is equivalent to 4 µg/ml
of amphotericin B which is a fungicidal concentration
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To further discern whether liquid isoflurane has similar
effects on C. albicans growth and morphogenesis under an
aerobic environment, Candida yeast cultures treated with
various concentrations of liquid isoflurane were allowed
to grow at 37°C with the syringe caps loosened (com-
pletely aerobic environment). The result was that growth
of Candida yeast was significantly inhibited at 0.2–0.3%
(Figure 5); however, lower concentrations of isoflurane
did not show an inhibitory effect on the formation of
hyphae as observed under semi-anaerobic conditions.
However, higher concentrations of 0.4% and above were
capable of inhibiting yeast multiplication as well as for-
mation of hyphae as depicted in Figure 6 as well.
However, the non-isoflurane-treated control culture
under semi-anaerobic conditions showed the ability to
form small hyphae after 16 hrs as shown in Figure 3 (Con-
trol). The growth inhibitory effect of 0.4% isoflurane was
equivalent to 4.0 µg/ml of amphotericin B. Both isoflu-
rane and amphotericin B inhibited formation of hyphae
in Candida, which is the form that is commonly associated
with pathogenicity.
An interesting observation pertains to the cellular volume
of yeast cells. Shrinkage in cellular volume of the yeast was
Effects of isoflurane on growth of Candida albicans in semi- anaerobic environment Figure 2
Effects of isoflurane on growth of Candida albicans in 
semi-anaerobic environment. The effect of various con-
centrations of isoflurane and anti-fungal Amphotericin B 4 
µg/ml (Amph B) on the growth of syringe culture was deter-
mined by optical density (OD) reading at 600 nm. Initial is the 
OD of starter culture. Columns represent the means (+/-) 
Standard error of the mean (SEM)) of four independent 
experiments. NS = Not significant
Effects of various concentrations of isoflurane on metabolic activity of candidal yeast culture Figure 1
Effects of various concentrations of isoflurane on metabolic activity of candidal yeast culture. Actively growing 
yeast cultures were treated with various concentrations of isoflurane (0.05% 0.8% v/v of media) and amphotericin B (4 µg/ml). 
The top of each syringe was tightly sealed to create semi-anaerobic environment. The metabolic activity of each syringe was 
determined by volume of displacement (an indicator of metabolic activity of Candidal yeast) in the syringe. Panel A shows vol-
ume of displacement in syringes (Smaller arrows indicate the levels) whereas Panel B is graphic representation of the displaced 
volume. Columns in the graph represent the means (+/- Standard error of the mean (SEM)) of four independent experiments.Journal of Translational Medicine 2006, 4:46 http://www.translational-medicine.com/content/4/1/46
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Viability Assay of Candida albicans culture treated with Isoflu- rane in semi-anaerobic environment Figure 4
Viability Assay of Candida albicans culture treated 
with Isoflurane in semi-anaerobic environment. For 
determination of viability assays 200 µl fungal culture from 
each syringe was added to 5 ml of prewarmed Lee's medium 
and allowed to grow at 37°C for 16 hrs. Photomicrographs 
of each fungal culture were captured by taking 100 µl of fun-
gal culture on glass slides and observing under the micro-
scope. Data presented in this figure is representative of three 
independent experiments.
Effects of various concentrations of isoflurane and anti-fungal  amphotericin B Figure 3
Effects of various concentrations of isoflurane and 
anti-fungal amphotericin B. Morphological changes in 
Candida albicans treated with various concentrations of iso-
flurane and amphotericin B in semi-anaerobic conditions. The 
magnification of each picture is 60×. The concentrations of 
isoflurane and amphotericin B are indicated in each panel. 
Data presented in this figure is representative of four inde-
pendent experiments.Journal of Translational Medicine 2006, 4:46 http://www.translational-medicine.com/content/4/1/46
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obvious from cultures treated with isoflurane at a concen-
tration of 0.2% (Fig. 3). The number of shrunken cells
increased with the higher concentrations of isoflurane
employed in these experiments. Amphotericin B as
described previously also showed cellular shrinkage in
our studies [12,13].
Discussion
Candida albicans is a dimorphic opportunistic pathogen
causing both superficial and systemic infections. The most
prominent factors involved in the pathogenesis of this
fungus are: capability to exist as both yeast and mycelium
with filamentous hyphae (dimorphism) depending on
host environment [14]. The hyphal form of this fungus is
more invasive and is also involved in the secretion of var-
ious proteases and lipases which facilitate tissue invasion
of the fungus [2]. Moreover, phenotypic switching
between hyphae and yeast form has been proposed as a
regulatory element in the pathogenesis of this fungus
[15]. In the past, efforts have been directed to identify
molecular mechanisms of phenotypic switching between
yeast and hyphal morphology of this fungus [16-18].
Like other fungi, an interesting aspect of Candida is its fac-
ultative nature [19] and as such can fulfill its energy
requirement either by aerobic respiration or anaerobic fer-
mentation. In our studies we determined antifungal activ-
ity of liquid isoflurane in both aerobic and semi-
anaerobic environment. Semi-anaerobic environment
was created due to the volatile nature of isoflurane, how-
ever, in our studies we also used an air-tight chamber and
exposed Candida cells with previously described, clini-
cally relevant concentrations of gaseous of isoflurane [1–
3 minimum alveolar concentration (MAC), a term used
by anesthetists for defining the strength of anesthetic
vapors] that inhibited formation of true hyphae from the
yeast (Data not illustrated in this manuscript). Moreover,
previous reports suggest that the sensitivity of C. albicans
to antifungal drugs particularly Terbinafine, neticonazole
and amphotericin B do not vary between aerobic and
anaerobic environments [20].
Effects of isoflurane on growth of Candida albicans in aerobic  environment Figure 6
Effects of isoflurane on growth of Candida albicans in 
aerobic environment. The effect of various concentra-
tions of isoflurane and anti-fungal Amphotericin B on the 
growth of syringe culture was determined by OD reading at 
600 nm. The data presented in this figure is an average of 
three independent experiments. Columns in the graph repre-
sent the means (+/-) Standard error of the mean (SEM).
Morphological changes in Candida albicans treated with vari- ous concentrations of isoflurane and amphotericin B in aero- bic conditions Figure 5
Morphological changes in Candida albicans treated 
with various concentrations of isoflurane and ampho-
tericin B in aerobic conditions. The effect of various con-
centrations of isoflurane and anti-fungal Amphotericin B was 
determined microscopically. Each culture was thoroughly 
mixed and 100 µl from each syringe was spread on micro-
scopic slides to capture images at (60×). Data presented in 
this figure is representative of three independent experi-
ments.Journal of Translational Medicine 2006, 4:46 http://www.translational-medicine.com/content/4/1/46
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Interestingly, liquid isoflurane treatments under aerobic
conditions inhibited multiplication of yeast in the same
manner as semi-anaerobic environments. However, in
aerobic conditions, formation of hyphae were observed in
fungal yeast treated with lower concentrations of isoflu-
rane (0.05 – 0.2%) in contrast to semi-anaerobic. It is not
clear if this phenotypic difference is due to nuances in tox-
icity of isoflurane and or different membrane conditions.
Despite these differences, higher concentrations of isoflu-
rane showed similar effects under both semi-aerobic and
aerobic environments.
As far as growth conditions are concerned, there are few
studies describing fungal growth in anaerobic environ-
ments in spite of the facultative nature of this fungus.
Efforts have been directed towards understanding the sur-
vival of C. albicans in anaerobic environments [21,22].
One study describes anaerobic morphogenesis of this fun-
gus in synthetic medium supplemented with yeast extract
or a combination of oleic acid, nicotinic acid and ammo-
nium chloride [23]. Although our findings are quite con-
trary to this study, i.e. limited formation of hyphae in the
semi-anaerobic environment was observed. Among
dimorphic fungi like Candida, the growth environment
plays a major role in the morphogenetic behavior of the
fungus. The growth conditions described in our study are
quite different than that reported by Dumitru et al [23].
The molecular mechanisms involved in the inhibitory
effects of liquid isoflurane on Candida yeast multiplica-
tion and hyphae formation require further exploration. It
is possible that cellular shrinkage (Please see Figures 3 and
5) that could lead to apoptosis of yeast cells is a mecha-
nism by which amphotericin B and isoflurane exert anti-
fungal activity.
Previously, it has been reported that volatile anesthetics
exert their effects on living cells by one of the three mech-
anisms: i) altering the lipid bilayer of the plasma mem-
brane, ii) modulation of membrane bound protein
function or iii) a combination of both which involves
anesthetic interaction with the lipid bilayer altering activ-
ity of membrane proteins [24]. Based on previous obser-
vations in Saccharomyces cerevisiae, it is possible that
isoflurane might inhibit nutrient-dependent growth
either by affecting membrane permeases or mRNA trans-
lation [25,26].
C. albicans acts as a silent enemy among healthy individu-
als and exists mainly by colonizing skin, and mucosal sur-
faces of oral, digestive tracts and genitalia. Defects in host
defense then permit the yeast to promulgate various ail-
ments. Amidst these ailments Candidal  vaginitis effects
almost 80 percent of healthy women once in their lifetime
as well as nearly every immunocompromised woman
[27,28]. Moreover, maternal Candida vaginitis can trans-
fer infection to newborn infants in the form of thrush and
diaper dermatitis [29]. Development of prophylactic
measures of the aforementioned situation would have
important public health implications for women and
infants. Besides superficial infections, Candida-associated
systemic infections are also on the rise, particularly among
bone marrow transplant patients who have shown higher
mortality associated with fungal infections [30]. Although
systemic usage of liquid volatile anesthetic via the intrave-
nous route is associated with adverse effects [31], emulsi-
fied isoflurane has been developed and intravenous
injections of this formulation has been proven to be safe
in animal models [32].
Another interesting aspect of this study is C. albicans
dimorphism which has been extensively studied at both
cellular and molecular levels [33-35]. The inhibitory
effects of isoflurane on formation of hyphae from various
Candidal species will provide the opportunity to study the
morphological shift in this opportunistic fungus. Further-
more, currently available robust molecular technologies
will assist in identifying genetic elements involved in the
dimorphic switch.
Our findings show that liquid isoflurane in culture inhib-
its yeast multiplication as well as formation of hyphae
from Candida. It will be essential to further explore the in
vivo significance of our in vitro data in order to translate
these findings into clinical application. However, in vitro
data from our studies strongly suggest that the antifungal
activity of liquid isoflurane equals or exceeds Amphoter-
icin B, a gold standard antimycotic currently in use that
unfortunately has extremely frequent and serious side
effects in humans. The highly lipophilic nature of isoflu-
rane compared to water-soluble Amph B may offer the
advantage of better penetration and bioavailability to
poorly vascularized tissues. The safety of topically applied
liquid isoflurane has been demonstrated in humans [36].
Furthermore, in a canine model, subarachnoid injection
of liquid volatile anesthetic agent did not cause perma-
nent motor or sensory neurological injury [37]. Further
investigations related to our findings are warranted.
Materials and methods
Fungal strain and materials
We used C. albicans strain H317, a clinical isolate from the
Centers for Disease Control and Prevention (Atlanta, GA),
that has been described previously [38]. Isoflurane, USP
grade was purchased from Baxter (Baxter Healthcare Cor-
poration, Deerfield, IL).
Growth media
C. albicans H317 cultures were grown in Lee's medium
[39] and maintained in 1% yeast extract, 2% peptone andJournal of Translational Medicine 2006, 4:46 http://www.translational-medicine.com/content/4/1/46
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2% dextrose (YPD) medium. Fresh Lee's medium was pre-
pared bi-weekly and stored at 4°C. An isolated C. albicans
colony growing on YPD plate was transferred into 20 ml
of pre-warmed Lee's medium and allowed to grow at
27°C for initiation of each starter culture.
Effects of liquid isoflurane on metabolic activity of C. 
albicans
Actively growing C. albicans yeast cultures at 27°C were
treated with isoflurane in 10 ml sterile plastic syringes
(Becton Dickinson, and Company). Briefly, 5.0 ml of fun-
gal suspensions were treated with isoflurane to final con-
centrations ranging between 0.05% – 0.8% (v/v). Upon
addition of isoflurane the syringe plunger and the top
cover were tightly closed and shaken for 5 seconds. As a
positive control, one of the culture syringes was treated
with amphotericin B (4.0 µg/ml), an antifungal agent
widely used in clinical practice. Negative control consisted
of Candida yeast culture without any treatment. All
syringes were tightly capped to create a semi-anaerobic
environment and were transferred to 37°C for 16 hours
with orbital shaking at 125 rpm. For experiments involv-
ing aerobic conditions, the syringe caps were loosened to
allow air exchange without risk of external contamina-
tion.
Effects of various concentrations of isoflurane and
amphotericin B on the metabolic activity of fungi were
assessed by volume displaced in the syringes under semi-
anaerobic conditions. The volume of displacement from
the fungal metabolic activity was recorded with a 3.2
mega pixel digital camera (Figure 1). Upon experiment
completion, the optical density (OD) of each culture was
also recorded at 600 nm. The effects of various concentra-
tions of isoflurane on the morphology of C. albicans were
recorded by morphological observations.
Isoflurane and viability of C. albicans
The viability of C. albicans upon treatment with isoflurane
for 16 hrs in semi-anaerobic and aerobic environments
was determined by adding 0.1 ml of culture from the
syringes culture in 2 ml of pre-warmed Lee's medium in
15 ml culture tubes. These tubes were shaken on a rotary
shaker for further 22 hrs at 37°C in cell-culture tubes.
Each culture was thoroughly mixed and 20 µl from each
syringe was spread on microscopic slides to capture live
images (Olympus inverted microscope with monitor and
digital camera, Olympus, Japan). Viability as well as mor-
phological changes were assessed and recorded digitally.
Statistical methods
All quantitative values are presented as means ± standard
error of the mean (SEM). Data comparing fungal metabo-
lism and fungal growth under different conditions were
subjected to ANOVA followed by Tukey-Kramer multiple
comparisons test. GraphPad statistical software (Graph-
Pad Software, Inc., San Diego, CA) was used to perform
the data analysis. Values of p < 0.05 were considered sta-
tistically significant.
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